Literature DB >> 6116608

Prolactin secretion during reserpine and syrosingopine treatment.

E Camanni, E Strumia, P Portaleone, G M Molinatti.   

Abstract

In 20 mild hypertensive women, reserpine induced a significant increase in mean plasma PRL, both under basal conditions (from 6.6 +/- 0.9 to 17.9 +/- 2.9 ng/ml), and on repeated determinations during the day. In contrast to reserpine, the administration of syrosingopine, a synthetic compound derived from reserpine, to the same subjects was not followed by a significant change in prolactin level. Beyond their pharmacological interest, these results are of clinical importance when considering that rauwolfia alkaloids are used for long term treatment, and that an increase in PRL levels is important in pathology, both in relation to the function of the hypophyseogonadal axis and in view of its possible facilitation of the growth and development of mammary cancer.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6116608     DOI: 10.1007/bf00615404

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  11 in total

Review 1.  Prolactin and breast carcinoma.

Authors:  F Smithline; L Sherman; D Kolodny
Journal:  N Engl J Med       Date:  1975-04-10       Impact factor: 91.245

2.  [Not Available].

Authors:  A J PLUMMER; W E BARRETT; R A MAXWELL; D FINOCCHIO; R A LUCAS; A E EARL
Journal:  Arch Int Pharmacodyn Ther       Date:  1959-03-01

3.  [Comparative study of the action of reserpine and of one of its esters, syrosingopine, on the genital tract and endocrine glands of the rat].

Authors:  H TUCHMANN-DUPLESSIS; L MERCIER-PAROT
Journal:  C R Hebd Seances Acad Sci       Date:  1960-08-01

4.  Increased prolactin levels during reserpine treatment of hypertensive patients.

Authors:  P A Lee; M R Kelly; J D Wallin
Journal:  JAMA       Date:  1976-05-24       Impact factor: 56.272

5.  Prolactin secretion in patients treated with various drugs: phenothiazines, tricyclic antidepressants, reserpine, and methyldopa.

Authors:  R W Turkington
Journal:  Arch Intern Med       Date:  1972-09

6.  Reserpine and breast cancer.

Authors: 
Journal:  Lancet       Date:  1974-09-21       Impact factor: 79.321

7.  Reserpine use in relation to breast cancer.

Authors:  O P Heinonen; S Shapiro; L Tuominen; M I Turunen
Journal:  Lancet       Date:  1974-09-21       Impact factor: 79.321

8.  Retrospective study of the association between use of rauwolfia derivatives and breast cancer in English women.

Authors:  B Armstrong; N Stevens; R Doll
Journal:  Lancet       Date:  1974-09-21       Impact factor: 79.321

9.  Reserpine and breast cancer in women in germany.

Authors:  H Kewitz; H J Jesdinsky; P M Schröter; E Lindtner
Journal:  Eur J Clin Pharmacol       Date:  1977-01-03       Impact factor: 2.953

10.  Reserpine and breast cancer.

Authors:  D Kodlin; N McCarthy
Journal:  Cancer       Date:  1978-02       Impact factor: 6.860

View more
  1 in total

Review 1.  Drug-induced changes in prolactin secretion. Clinical implications.

Authors:  K Hell; H Wernze
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 Nov-Dec
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.